SIOX — Sio Gene Therapies Share Price
0.000.00%
Last trade - 00:00- $33.95m
- -$12.17m
- 22
- 39
- 77
- 43
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.75 | ||
| Price to Tang. Book | 0.75 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -65.09% | ||
| Return on Equity | -47.5% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Mar | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sio Gene Therapies Inc. was a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The Company has not generated any revenue.
Directors
- Frank Torti CHM (42)
- Pavan Cheruvu CEO (39)
- David Nassif CFO (67)
- Gavin Corcoran OTH (59)
- Atul Pande LED (67)
- Eric Venker DRC (34)
- Berndt Modig IND (62)
- Senthil Sundaram IND (43)
- Kristiina Vuori IND (53)
- Last Annual
- March 31st, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- November 12th, 2020
- Public Since
- June 11th, 2015
- No. of Shareholders
- 3
- No. of Employees
- 12
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 73,975,196
- Address
- 1501 Broadway, 12Th Floor, NEW YORK, 10036
- Web
- https://siogtx.com/
- Phone
- +1 3026365400
- Auditors
- Ernst & Young LLP
Upcoming Events for SIOX
Similar to SIOX
Acacia Diversified Holdings
Pink Sheets on Nasdaq
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
FAQ
What is the Sio Gene Therapies share price?
As of Today at 18:20 UTC, shares in Sio Gene Therapies are trading at $0.46. This share price information is delayed by 15 minutes.
How has the Sio Gene Therapies share price performed this year?
Shares in Sio Gene Therapies last closed at $0.46 and the price had moved by +0.9% over the past 365 days. In terms of relative price strength the Sio Gene Therapies share price has underperformed the S&P500 Index by -9.6% over the past year.
What are the analyst and broker recommendations for Sio Gene Therapies?
The overall consensus recommendation for Sio Gene Therapies is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Sio Gene Therapies dividend yield?
Sio Gene Therapies does not currently pay a dividend.
Does Sio Gene Therapies pay a dividend?
Sio Gene Therapies does not currently pay a dividend.
When does Sio Gene Therapies next pay dividends?
Sio Gene Therapies does not currently pay a dividend.
How do I buy Sio Gene Therapies shares?
To buy shares in Sio Gene Therapies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sio Gene Therapies?
As of the previous close price of $0.46, shares in Sio Gene Therapies had a market capitalisation of $33.95m.
Where are Sio Gene Therapies shares listed?
Here are the trading details for Sio Gene Therapies:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: SIOX
What kind of share is Sio Gene Therapies?
Based on an overall assessment of its quality, value and momentum Sio Gene Therapies is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sio Gene Therapies share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Sio Gene Therapies share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sio Gene Therapies. Over the past six months, its share price has outperformed the S&P500 Index by +11.7%.
As of the last closing price of $0.46, shares in Sio Gene Therapies were trading +16.99% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sio Gene Therapies PE Ratio?
The Sio Gene Therapies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.46.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sio Gene Therapies?
Sio Gene Therapies' management team is headed by:
- Frank Torti - CHM
- Pavan Cheruvu - CEO
- David Nassif - CFO
- Gavin Corcoran - OTH
- Atul Pande - LED
- Eric Venker - DRC
- Berndt Modig - IND
- Senthil Sundaram - IND
- Kristiina Vuori - IND